Immediate Impact
53 standout
Citing Papers
The present and future of bispecific antibodies for cancer therapy
2024 Standout
Glioblastoma Therapy: Past, Present and Future
2024 Standout
Works of Feng Luo being referenced
Phase I Trial of Weekly Tigatuzumab, an Agonistic Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5)
2010
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Feng Luo | 36 | 122 | 42 | 63 | 52 | 38 | 300 | |
| Tingting Gong | 30 | 71 | 66 | 32 | 27 | 27 | 326 | |
| Wenjuan Wang | 32 | 91 | 31 | 77 | 61 | 28 | 362 | |
| Rishabh Sharma | 12 | 51 | 54 | 30 | 23 | 25 | 325 | |
| Hongping Tang | 21 | 119 | 31 | 65 | 30 | 24 | 308 | |
| Guldeep Uppal | 30 | 76 | 28 | 47 | 33 | 33 | 259 | |
| Jun Huang | 74 | 118 | 45 | 32 | 37 | 31 | 327 | |
| Mazaher Maghsoudloo | 11 | 122 | 62 | 66 | 53 | 34 | 254 | |
| Xiaojing Kang | 14 | 95 | 26 | 61 | 38 | 37 | 260 | |
| David Farnell | 23 | 55 | 34 | 48 | 53 | 20 | 337 | |
| Xiao Yu Zhang | 15 | 110 | 22 | 50 | 27 | 51 | 312 |
All Works
Login with ORCID to disown or claim papers
Loading papers...